Xiangying Chu

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)

Max Kates, Xiangying Chu, Noah M. Hahn et al. · European Urology Focus · 2023 · 48 citations · Full text

Medicine, Oncology, Urology +12

Association of Disparities in Family History and Family Cancer History in the Electronic Health Record With Sex, Race, Hispanic or Latino Ethnicity, and Language Preference in 2 Large US Health Care Systems

Daniel Chavez‐Yenter, Melody S. Goodman, Yuyu Chen et al. · JAMA Network Open · 2022 · 44 citations · Full text

Computing, Biomedical Informatics, Health Informatics +14

PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy

Petros Grivas, Vadim S. Koshkin, Xiangying Chu et al. · European Urology Oncology · 2023 · 25 citations

Medicine, Oncology, Urology +15

Racial and Ethnic Diversity Among Students, Graduates, and Faculty in Biostatistics and Epidemiology, 2010-2020

Melody S. Goodman, Jemar R. Bather, Xiangying Chu et al. · Public Health Reports · 2022 · 12 citations · Full text

Public Health, Biostatistics, Higher Education +14

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Heather A. Parsons, Timothy Blewett, Xiangying Chu et al. · medRxiv · 2023 · 12 citations · Full text

Medicine, Molecular Genetics, Oncology +17